Edition:
United States

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

6.60USD
23 Feb 2018
Change (% chg)

$0.04 (+0.61%)
Prev Close
$6.56
Open
$6.49
Day's High
$6.74
Day's Low
$6.49
Volume
7,728
Avg. Vol
11,994
52-wk High
$9.36
52-wk Low
$4.94

Chart for

About

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-re... (more)

Overall

Beta: --
Market Cap(Mil.): $81.41
Shares Outstanding(Mil.): 12.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.65

* LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND ANNOUNCES DATE OF ITS ANNUAL MEETING OF STOCKHOLDERS

Feb 23 2018

BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy

* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage:

Jan 16 2018

BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders

* LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2jdjIfs) Further company coverage:

Dec 08 2017

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

Nov 22 2017

BRIEF-Leap Therapeutics announces $18 million private placement offering

* Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​

Nov 15 2017

BRIEF-Leap Therapeutics qtrly loss per share $0.73

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

Nov 13 2017

BRIEF-Leap Therapeutics announces collaboration with EORTC

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

Sep 08 2017

Earnings vs. Estimates